F M Investments LLC Makes New Investment in Akero Therapeutics, Inc. (NASDAQ:AKRO)

F M Investments LLC bought a new stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 45,778 shares of the company's stock, valued at approximately $1,274,000. F M Investments LLC owned 0.07% of Akero Therapeutics at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. SG Americas Securities LLC lifted its position in shares of Akero Therapeutics by 4,022.1% during the 4th quarter. SG Americas Securities LLC now owns 597,993 shares of the company's stock valued at $16,636,000 after buying an additional 583,486 shares in the last quarter. Great Lakes Advisors LLC purchased a new position in Akero Therapeutics during the fourth quarter valued at approximately $5,380,000. Springhill Fund Asset Management HK Co Ltd bought a new position in shares of Akero Therapeutics in the fourth quarter worth approximately $4,206,000. abrdn plc increased its stake in shares of Akero Therapeutics by 118.7% in the fourth quarter. abrdn plc now owns 269,782 shares of the company's stock worth $7,505,000 after purchasing an additional 146,424 shares in the last quarter. Finally, Exome Asset Management LLC bought a new stake in shares of Akero Therapeutics during the 3rd quarter valued at $2,212,000.

Insider Buying and Selling at Akero Therapeutics

In related news, COO Jonathan Young sold 607 shares of the stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $44.88, for a total transaction of $27,242.16. Following the sale, the chief operating officer now owns 200,540 shares in the company, valued at approximately $9,000,235.20. This represents a 0.30 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Andrew Cheng sold 30,000 shares of Akero Therapeutics stock in a transaction on Thursday, April 10th. The stock was sold at an average price of $35.23, for a total transaction of $1,056,900.00. Following the transaction, the chief executive officer now directly owns 624,324 shares of the company's stock, valued at $21,994,934.52. The trade was a 4.58 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have purchased 341,309 shares of company stock worth $15,863,578 and have sold 278,385 shares worth $13,345,929. Company insiders own 7.94% of the company's stock.

Remove Ads

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. Canaccord Genuity Group increased their price target on Akero Therapeutics from $56.00 to $73.00 and gave the stock a "buy" rating in a research note on Tuesday, January 28th. HC Wainwright upped their price objective on Akero Therapeutics from $72.00 to $75.00 and gave the stock a "buy" rating in a research note on Monday, March 3rd. UBS Group lifted their target price on Akero Therapeutics from $42.00 to $109.00 and gave the company a "buy" rating in a research note on Friday, January 31st. Bank of America raised Akero Therapeutics from a "neutral" rating to a "buy" rating and boosted their price target for the stock from $35.00 to $63.00 in a report on Thursday, January 30th. Finally, Morgan Stanley reaffirmed an "overweight" rating on shares of Akero Therapeutics in a report on Sunday, March 2nd. Nine analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $76.29.

Akero Therapeutics Price Performance

Shares of AKRO stock traded up $0.48 on Tuesday, reaching $38.08. The company's stock had a trading volume of 652,762 shares, compared to its average volume of 857,673. The stock's fifty day simple moving average is $44.46 and its 200-day simple moving average is $35.98. Akero Therapeutics, Inc. has a 1 year low of $17.86 and a 1 year high of $58.40. The company has a market capitalization of $3.03 billion, a price-to-earnings ratio of -10.15 and a beta of -0.18. The company has a current ratio of 17.25, a quick ratio of 17.25 and a debt-to-equity ratio of 0.05.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last posted its earnings results on Friday, February 28th. The company reported ($0.99) earnings per share for the quarter, missing analysts' consensus estimates of ($0.98) by ($0.01). Analysts forecast that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current fiscal year.

Akero Therapeutics Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.